Replies to post #6949 on MultiCell Technologies Inc (MCET)

[paulenater]

Agree and so excited to be involved with this board and stock. With Pharmaceutical shopping around for the next best thing with $$$Billions$$$ at there disposal; my guess is that MCET looks very atractive to them.

MCET is involved in the new frontier in medicine and have a head start with these already in the pipline.


Discovery Platform & Disease Targets
MultiCell Technologies’ discovery platform is focused on approaches to yield innovative targets and therapeutic strategies, and is based on patented technologies which:

•Modulate the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF) affecting over 70% of all persons with multiple sclerosis.
•Control the immune response at transcriptional and translational levels through double-stranded RNA (dsRNA)-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, to treat cancer.
•Enhance antigen presentation to the immune system by targeting antigen epitopes for optimal processing via the Fcg receptors through the novel generation of recombinant immunoglobulins for the treatment of cancer.
•Enable generation and manipulation of normal or cancerous stem cells applicable to discovery, design, development of new therapies, diagnostics, and research tools for liver diseases.
Discovery Platform Advantages & Disease Targets

Our therapeutic development platform has several competitive advantages:

•The ability to increase the production of adrenaline by selectively modulating noradrenergic neurons with little or no effect on seratoninergic neurons thereby inhibiting the reuptake of noradrenaline (norepinephrine) while promoting increased tyrosine hydroxylase activity, a key regulatory enzyme in noradrenaline/adrenaline biosynthesis pathway. MCT-125, an innovative drug combination currently in Phase 2b clinical development for the treatment of primary multiple sclerosis-related fatigue (PMSF) is based on this technology.
•Unlike other immune modulating compounds, our novel synthetic double-stranded RNA (dsRNA) can specifically control the immune response through Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or act directly on cancer cells, affording it the potential for use in a broader spectrum of therapeutic applications in oncology and beyond. This concept has yielded two investigational agents: (i) MCT-465 a high molecular weight dsRNA immune enhancing agent for the treatment of cancer; and (ii) MCT-485, a low molecular weight dsRNA anti-tumor cytotoxic agent for the treatment of certain cancers.
•Our therapeutic antibody technology, Epitope-based T-cell Immunotherapy, can more effectively deliver epitope peptides to the immune system than traditional methods. Coupling our synthetic dsRNA platform technology with our therapeutic antibody technology, maximizes the potential of disease-associated epitope peptides, creating more effective anticancer therapeutics. MCT-475 as an investigational therapeutic antibody agent used in conjunction with MCT-465 for the treatment of various cancers such as breast carcinoma.
•The ability to isolate and characterize normal stem cells from liver, and potentially isolate and characterize cancer stem cells from liver tumor cells, as discovery tools to support identification of novel therapeutic targets for the treatment of primary hepatocellular carcinoma.